Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil

被引：20
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Jennings, LW [1 ]
Christensen, LL [1 ]
Molmenti, EP [1 ]
Sanchez, EQ [1 ]
Levy, MF [1 ]
Goldstein, RM [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Transplantat Serv, Dallas, TX 75246 USA
来源：
TRANSPLANTATION PROCEEDINGS | 2002年 / 34卷 / 05期
关键词：
D O I：
10.1016/S0041-1345(02)03023-3
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1563 / 1564
页数：2
相关论文
共 50 条
  • [1] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [2] Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients
    Kornberg, A.
    Kuepper, B.
    Wilberg, J.
    Tannapfel, A.
    Thrum, K.
    Baerthel, E.
    Hommann, M.
    Settmacher, U.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 295 - 301
  • [3] A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C
    Jain, A
    Kashyap, R
    Demetris, AJ
    Eghstesad, B
    Pokharna, R
    Fung, JJ
    LIVER TRANSPLANTATION, 2002, 8 (01) : 40 - 46
  • [4] Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients?
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Molmenti, EP
    Klintmalm, GB
    TRANSPLANTATION, 2000, 69 (08) : S120 - S120
  • [5] Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Sanchez, EQ
    Molmenti, EM
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [6] Mycophenolate mofetil reduces rejection rates in hepatitis C positive liver transplant recipients.
    Baillie, GM
    Taber, DJ
    Rogers, J
    Lin, A
    Baliga, P
    Chavin, KD
    HEPATOLOGY, 2002, 36 (04) : 655A - 655A
  • [7] Natural history of recurrence of hepatitis C (HEP CR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS).
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [8] Mycophenolate mofetil monotherapy in liver transplant recipients
    Kriss, Michael
    Sotil, Eva U.
    Abecassis, Michael
    Welti, Mary
    Levitsky, Josh
    CLINICAL TRANSPLANTATION, 2011, 25 (06) : E639 - E646
  • [9] The use of mycophenolate mofetil in liver transplant recipients
    Detry, O
    de Roover, A
    Delwaide, J
    Meurisse, M
    Honoré, P
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) : 1949 - 1957
  • [10] Hepatitis C recurrence in liver transplant recipients
    Kizilisik, TA
    AlSebayel, M
    Hammad, A
    AlTraif, I
    Ramirez, CG
    Abdulla, A
    TRANSPLANTATION PROCEEDINGS, 1997, 29 (07) : 2875 - 2877
12345